



You are entering a medical section of the Pfizer Landing Page. All materials presented here are for purposes of scientific exchange. They are NOT presented for any promotional purpose

Pfizer Posters

Poster sessions will be held on site and virtually.

Poster Session 1

Wednesday, December 8 7:00 AM – 8:30 AM CST

Palbociclib P1-18-04

Feasibility of palbociclib in women aged 70 and older with advanced breast cancer pretreated with systemic treatment in PALOMAGE study

Brain E

View Presentation

Palbociclib P1-18-05

Early changes in circulating tumor DNA (ctDNA) and impact on clinical outcomes in patients with advanced breast cancer receiving the CDK4/6 inhibitor palbociclib: Genotyping results from POLARIS

Tripathy D

View Presentation

Palbociclib P1-18-13

Efficacy and safety of palbociclib plus endocrine therapy in Black and Hispanic patients with hormone receptor positive/human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/ HER2– ABC)

Isaacs C

View Presentation

Palbociclib P1-18-20

Real-world effectiveness of palbociclib plus letrozole vs letrozole alone for metastatic breast cancer with lung/liver metastases: Flatiron database analysis

Brufsky A

View Presentation

Palbociclib P1-18-25

Real-world quality of life (QoL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2–negative (HER2–), advanced breast cancer (ABC) treated with palbociclib: A patient-reported outcome (PRO) analysis from POLARIS

Karuturi M

View Presentation

Palbociclib P1-18-29

Male patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) receiving palbociclib in the real-world: patient characteristics, treatment patterns, and outcomes from the POLARIS study

Blum J

View Presentation

Poster Spotlight Session 2

Wednesday, December 8 7:00 AM – 8:30 AM CST

Palbociclib PD2-07

Impact of using cross-platform gene expression profiling technologies and computational methods for intrinsic breast cancer subtyping in PALOMA-2 and PALLET

Cheang M

View Presentation

Poster Session 2

Wednesday, December 8 5:00 PM – 6:30 PM CST

Talazoparib P2-09-05

Germline *BRCA1/2* mutation testing in human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC): A real-world study in the Syapse Learning Health Network (LHN)

Niyazov A

View Presentation

Talazoparib P2-09-08

Impact of race on clinical outcomes among patients (pts) with HER2– advanced breast cancer (ABC) and germline *BRCA1/2* mutation(s) (g*BRCA1/2*mut): Results from a US real-world study

Whitaker K

View Presentation

Ongoing Trials Poster Session 2

Thursday, December 9 5:00 PM – 6:30 PM CST

Palbociclib OT2-19-04

European treatment patterns and outcomes associated with first-line CDK4/6 inhibition and hormonal therapies assessed in a real-world noninterventional study (EUCCHARIS)

Law E

View Presentation

Poster Session 5

Friday, December 10 7:00 AM – 8:30 AM CST

Palbociclib P5-14-08

Effectiveness of palbociclib plus letrozole vs letrozole in US Hispanic and African American patients with metastatic breast cancer: Flatiron database analysis

Rugo HS

View Presentation

Talazoparib P5-13-08

Identification of PD-L1+ status as a candidate predictive biomarker of response to talazoparib (TALA) in the phase 3 EMBRACA study

Rugo HS

View Presentation

CDK 246 P5-16-06

A first-in-human phase 1/2a dose escalation/expansion study of the first-in-class CDK2/4/6 inhibitor PF-06873600 alone or with endocrine therapy in patients with breast or ovarian cancer

Yap TA

View Presentation

Poster Spotlight Session 13

Friday, December 10 7:00 AM – 8:30 AM CST

ARV-471 PD-13-08

First in-human safety and activity of ARV-471, a novel PROTAC® estrogen receptor degrader, in ER+/HER2- locally advanced or metastatic breast cancer

Hamilton E

View Presentation